Geneva, March 23 -- International Clinical Trials Registry received information related to the study (NCT07459751) titled 'A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung Cancer' on March 5.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Shanghai Henlius Biotech
Condition:
Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
Intervention:
Drug: HLX43
Drug: HLX43+HLX07
Recruitment Status: Not recruiting
Phase: Phase 2/Phase 3
Date of First E...